Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Uproleselan update: moving forward for R/R AML

Daniel DeAngelo • 8 Dec 2019
ASH 2019
Acute Myeloid Leukemia Leukemia Uproleselan

Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the latest data on uproleselan (GMI-1271), a novel E-selectin antagonist, in acute myeloid leukemia (AML). This includes the upcoming phase 3 registration trial in the relapsed/refractory setting (NCT03616470) and work showing that uproleselan can overcome the chemotherapy resistance that high E-selectin ligand expression contributes to. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Daniel DeAngelo

1:36
IMGN632: a novel CD123-targeted antibody-drug conjugate for R/R BPDCN
Daniel DeAngelo • 3 Dec 2020
1:36
Diagnostic pathology is crucial to guide treatment options
Daniel DeAngelo • 3 Dec 2020
2:29
ASH 2020: Treatment advances in mastocytosis
Daniel DeAngelo • 3 Dec 2020
3:57
Major ALL treatment updates at ASH 2020
Daniel DeAngelo • 3 Dec 2020

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals